Author

Amanda N. Morris

An infectious diseases clinical pharmacist in Bangor, Maine, Amanda N. Morris, PharmD, BCIDP, directs medication review for an inpatient antimicrobial stewardship service. She finished a specialized PGY2 pharmacy residency in infectious diseases before taking on her role evaluating broad-spectrum antibiotic orders throughout the hospital. Morris consults with medical teams on dose optimization, culture interpretation, and interventions favoring shorter, targeted courses of therapy. She collaborates with physicians and nursing units to update treatment pathways and monitor hospital-wide resistance trends, helping clinical teams make sound therapeutic choices for complicated bloodstream and tissue infections.

Pseudomonas Coverage: Antibiotics and Treatment Strategies
Enterococcus Faecalis Antibiotic Treatments and Resistance
Enterobacter Cloacae Treatment: Current Antibiotic Approaches
Why Is Dexamethasone Given Before Antibiotics in Meningitis?
Viral Entry Inhibitors: Key Players in Antiviral Therapy
Stenotrophomonas Maltophilia: What Antibiotics Are Used?
Streptococcus Pneumoniae: Antibiotics and Resistance
Clindamycin Resistance: Mechanisms, Bacteria & Detection
Ceftriaxone’s Efficacy Against E. coli: Mechanisms and Challenges
Ciprofloxacin in MRSA Treatment: Mechanisms and Alternatives
Innovative Treatments for Burkholderia Cepacia Infections
Ceftazidime: Mechanism, Activity, and Resistance in Bacterial Defense
Meropenem vs. Pseudomonas Aeruginosa: Mechanisms and Therapies
Ceftriaxone and Alternatives for Treating Pseudomonas Infections
Mechanisms of Antibiotics Against Gram-Positive Cocci
Innovative Antifungal Strategies for Candida Dubliniensis Treatment
Clindamycin’s Impact on C. difficile Infection and Resistance
Levofloxacin in Pseudomonas Infection Treatment: A Comprehensive Guide
Cefazolin and E. coli: Mechanisms, Resistance, and Clinical Impact
Understanding ESBL Resistance and Oral Antibiotic Options
Carbapenem Use and Resistance in Infection Treatment